Ligand binding to a G protein–coupled receptor captured in a mass spectrometer by Yen HY et al.
SC I ENCE ADVANCES | R E S EARCH ART I C L EB IOCHEM ISTRY1Chemistry Research Laboratory, University of Oxford, South Parks Road, Oxford
OX1 3QZ, UK. 2OMass Technologies Ltd., Centre for Innovation and Enterprise,
Begbroke Science Park, Woodstock Road, Oxford OX5 1PF, UK. 3CAS Key Labora-
tory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Acade-
my of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, China. 4School
of Life Science and Technology, ShanghaiTech University, 99 Haike Road, Pudong,
Shanghai 201203, China. 5Departments of Chemistry and Biochemistry, University
of Oxford, Oxford OX1 3QU, UK.
*These authors contributed equally to this work.
†Present address: UCB Celltech, 216 Bath Road, Slough SL1 3WE, UK.
‡Corresponding author. Email: carol.robinson@chem.ox.ac.uk









License 4.0 (CC BY).Ligand binding to a G protein–coupled receptor
captured in a mass spectrometer
Hsin-Yung Yen,1* Jonathan T. S. Hopper,2* Idlir Liko,1,2* Timothy M. Allison,1 Ya Zhu,3
Dejian Wang,3,4 Monika Stegmann,5† Shabaz Mohammed,5 Beili Wu,3,4 Carol V. Robinson1‡
G protein (heterotrimeric guanine nucleotide–binding protein)–coupled receptors belong to the largest family
of membrane-embedded cell surface proteins and are involved in a diverse array of physiological processes.
Despite progress in the mass spectrometry of membrane protein complexes, G protein–coupled receptors
have remained intractable because of their low yield and instability after extraction from cell membranes.
We established conditions in the mass spectrometer that preserve noncovalent ligand binding to the human
purinergic receptor P2Y1. Results established differing affinities for nucleotides and the drug MRS2500 and
link antagonist binding with the absence of receptor phosphorylation. Overall, therefore, our results are
consistent with drug binding, preventing the conformational changes that facilitate downstream signaling.
More generally, we highlight opportunities for mass spectrometry to probe effects of ligand binding on
G protein–coupled receptors.INTRODUCTION
G protein (heterotrimeric guanine nucleotide–binding protein)–
coupled receptors (GPCRs) are the largest family ofmembrane proteins
in vertebrates and account for nearly 40% of targets for current drugs
(1). The entire GPCR family has ~1000members that share a conserved
topology with seven transmembrane helices and are categorized into
six classes according to structural and functional criteria (2, 3). GPCR
activation is thought to involve rearrangement of the transmembrane
helices induced by ligand binding, one of the critical steps that triggers
activation for downstream signaling with G proteins and modulation
of cellular physiology (4, 5). Agonist-induced conformational changes
of GPCRs also expose sites on the intracellular regions that can be
modified by phosphorylation (6). This combined process of confor-
mational change and posttranslational modification (PTM) allows
the receptor to interact with a number of GPCR-interacting proteins
to desensitize GPCRs (7, 8), the arrestin family being the most exten-
sively studied.
The humanpurinergic receptor P2Y1R, a classAGPCR, functions as
a receptor for extracellular adenosine 5′-diphosphate (ADP) and aden-
osine 5′-triphosphate (ATP) and regulates many physiological pro-
cesses including thrombosis (9–13). P2Y1R is fully activated by ADP
to facilitate platelet aggregation via calcium wave propagation. Inhibi-
tion of P2Y1R activation leads to a significant decrease in ADP-induced
platelet aggregation (14). Thus, P2Y1R acts as a key antithrombotic drug
target (10). MRS2500 {(1′R,2′S,4′S,5′S)-4-(2-iodo-6-methylamino-purine-
9-yl)-1-[(phosphato)methyl]-2-(phosphato)bicyclo[3.1.0]-hexane} is a
potent antagonist of P2Y1R, inhibiting ADP-platelet aggregation and
reducing arterial thrombosis (15–17). X-ray crystal structures of ligand-bound P2Y1R and mutagenesis studies reveal that binding to MRS2500
involves the samepocket responsible forADPbinding.MRS2500, in con-
trast to ADP binding, stabilizes the receptor in an inactive conformation
by reducing the conformational flexibility of helices VI and VII, resulting
in a severe loss of receptor activity (18).
Nondenaturing or native mass spectrometry (MS) has emerged as a
powerful technology for studying intact membrane protein assemblies
(19). Modified Orbitrap MS can provide the resolving power necessary
to define noncovalent interactions of membrane proteins with small
molecules, as well as to identify protein modifications, including glyco-
sylation and phosphorylation (20–22). To date, although excellent MS
data have been recorded for largemembrane complexes including intact
rotary adenosine triphosphatases (23) and for peptides derived from
GPCRs following chemical cross-linking or hydrogen deuterium ex-
change (24, 25), it has been challenging to study intact GPCRs with lig-
and bindingmaintained.We attribute this challenge to the instability of
GPCRs when removed from their native membranes in micelles, a
property that is further compounded by their low expression yield and
the requirement to remove the micelle in the mass spectrometer by ac-
tivation in the gas phase.RESULTS
After extensive detergent screening, we were able to optimize solution
and MS conditions to enable preservation of folded ligand-bound hu-
man P2Y1R. The receptor, which was purified from insect cells as de-
scribed previously (18), was introduced into the gas phase from amixed
detergent micelle, containing n-dodecyl b-D-maltoside (DDM), choles-
terol, and foscholine (Fig. 1A; see Materials andMethods). This micelle
was then destabilized in the gas phase, through collisions with neutral
gas molecules, enabling us to obtain mass spectra of the naked receptor
and consequently define the mass of P2Y1R in its apo state (table S1).
In the mass spectrum, in addition to the series assigned to the apo
protein, a predominant adduct peakwas observedwith amass increase
of 426.7 ± 2 Da, corresponding inmass to noncovalent binding of ADP
(Fig. 1B).We did not detect ATP binding to the receptor, althoughATP
was added during the early stages of the purification (see Materials and
Methods). We conclude that ATP is hydrolyzed such that ADP is re-
tained as the endogenous ligand of P2Y1R.Observation of ADPbinding1 of 6
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gas phase.We also observed significant phosphorylation of the receptor,
enabling us to explore the effects of this modification on ADP binding.
We noted that the ratio of the peak intensities assigned to the phos-
phorylated forms of apo and ADP-bound receptor is indistinguishable
within error (39.6 and 41.5%), as determined byUniDec (UniversalDe-
convolution) software (26). This correspondence implies that the
phosphorylation process is not affected by the binding of ADP/ATP
to P2Y1R.
To establish whether drug binding to P2Y1R could be preserved
within the gas phase, we purified the receptor in the presence of MRS2500
(18). Under MS conditions similar to those used for the apo protein,
we observed a single charge state distribution corresponding to the the-
oretical mass of the receptor-drug complex (Fig. 2 and table S1). The
apo protein was not observed in the mass spectrum, implying that
100% drug binding is maintained throughout purification and during
transfer into the gas phase. High-energy collisions, designed to activate
the complex, led to dissociation of MRS2500, likely through unfolding
of the GPCR (fig. S1). We also observed a significant population of zinc
binding that was assigned to the rubredoxin fusion protein used forYen et al., Sci. Adv. 2017;3 : e1701016 16 June 2017x-ray crystallography of P2Y1R-MRS2500 (18). In the presence of
the drug, we could not detect any of the phosphorylated form of
P2Y1R, indicating that MRS2500 binding inhibits phosphorylation
(6). Our mass spectra of the receptor-drug complex also allow us to rule
out simultaneous binding to endogenous ADP, thereby confirming the
higher affinity of P2Y1R for MRS2500 over ADP (15, 17).
Given our observation of endogenous nucleotide binding, we
examined the ability of differentmolar ratios of exogenousATP to com-
pete withMRS2500 (Fig. 2).We incubated the receptor-drug complex
at 37°C for 30 min with 0.25 and 0.5 molar ratios of ATP and found
that both ATP and drug-bound P2Y1R are observed with these low
concentrations. Incubation at higher ATP concentrations (1:2 molar
P2Y1R/ATP) raised the possibility of a second ATP-binding site and
demonstrated complete displacement of MRS2500 by substoichio-
metric quantities of ATP.
Because we observed that the antagonist MRS2500 inhibits phos-
phorylation of P2Y1R, whereas binding of ADP/ATP does not, we set
out to establish a link between drug binding and phosphorylation. We
identified phosphosites in apo P2Y1R, without addition of drug, using
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Fig. 1. Schematic representation of the experiment designed to preserve the folded structure of the GPCR during transfer from solution to gas phase and
resulting mass spectra, revealing binding of an endogenous ligand. (A) Mixed micelles composed of cholesterol and detergent are formed in solution encapsulat-
ing P2Y1R. Gas phase activation is used to release the GPCR, effecting transfer from solution to gas phase while retaining the ligand-binding site. nESI, nanoelectrospray
ionization. (B) MS of wild-type P2Y1R reveals two peaks for each charge state corresponding to apo (blue square) and binding of endogenous ADP (magenta circle).
Expansion of the 11+ charge state (blue background) shows significant phosphorylation (green) of apo and ligand-bound forms. m/z, mass/charge ratio.2 of 6
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are not phosphorylated in the presence of MRS2500, implying that drug
binding during preparation inhibits the phosphorylation reaction. If
these three phosphorylated residues at the C terminus modulate the
structure and dynamics of the GPCR, then we would anticipate a re-
duction in drug binding to the phosphorylated form of the protein
due to restricted access to the binding site. To test this hypothesis, we
incubated MRS2500 with a mixture of unmodified and the phos-
phorylated apo form of the protein. Even though the level of phos-Yen et al., Sci. Adv. 2017;3 : e1701016 16 June 2017phorylation is quite low (sum of all three sites, <40%), we found that
drug binding was predominantly to the nonphosphorylated form,
with a reduced population (~20%) of MRS2500 bound to the phos-
phorylated receptor (Fig. 3).
Because the activation of GPCR kinases (GRKs) relies on direct
docking with active GPCRs (27), we hypothesize that the restrained
conformation of MRS2500-P2Y1R restricts access of GRKs and there-
by inhibits receptor phosphorylation. This finding is consistent with
recent molecular dynamics simulations, wherein an ionic lock was
found to tether helices in the MRS2500-P2Y1R complex but was ab-
sent in the ADP-bound receptor (28). Because GPCR phosphorylation
is considered a critical step that facilitates binding to interacting pro-
teins such as arrestin (29, 30), our observations implicate MRS2500 in
modulating P2Y1R function not only through prevention of dynamics
but also through inhibition of phosphorylation-dependent protein in-
teractions. Moreover, preferential MRS2500 binding to the nonphos-
phorylated receptor highlights the possibility of an allosteric effect of
C-terminal phosphorylation, hindering access to the drug-binding site.
This phenomenon was also reported in the study of b2-adrenoceptor
(31), and it raises the potential of GRKs to modulate the pharmacology
of MRS2500.DISCUSSION
By developing and applying MS to retain ligand binding in a GPCR,
we have demonstrated binding of the endogenous ligand ADP to both
unmodified and phosphorylated forms of the receptor. We have also
shown that high concentrations of ATP attenuate binding of ADP but
do not completely displace ADP (fig. S2), in line with the known abil-
ity of ATP to act as a partial agonist/antagonist depending on the ex-
pression level of P2Y1R (32–34). By contrast, we have shown that ATP
at the same levels can displace MRS2500 completely, which subse-
quently enables ADP binding to P2Y1R to trigger activation of the re-
ceptor. Our observation is supported by reports of a weak competition
of MRS2500 by saturated 2-methyl-thio-ADP on the cell membranes
of Sf9 insect cell overexpressing P2Y1R (35), and it provides a rationale
for the moderate side effects reported during treatment with MRS2500
(15, 17).
The possibility of an additional binding site for ATP in P2Y1R has
also been raised (36), and although the presence of excess ATP used in
our experiments means that we cannot discount nonspecific binding,
our data are consistent with the existence of a second ATP-binding
site. Of particular note in our study is the observation that the drug
inhibits phosphorylation and binds preferentially to the unphospho-
rylated receptor. These observations highlight the significant advantages
of MS over other biophysical approaches because the influence of
PTMs can be related directly to drug binding.
Overall, given the well-documented challenges of isolating suffi-
cient quantities of GPCRs, with folding and ligand binding abilities
preserved, our study, which is relatively rapid (hours) and requires
only tens of microliters at micromolar concentrations of protein, ex-
emplifies a powerful new technology. Moreover, because GPCRs are
the largest class of drug targets in the human genome, the molecular
basis of their activation, the competitive binding of their inhibitors,
and the impact of PTMs on downstream coupling and ligand binding
provide invaluable information for drug development. This MS ap-
proach therefore represents a significant advance over many current





























































































































Fig. 2. Mass spectrum of P2Y1R isolated with drug and incubated with dif-
ferent molar ratios of ATP. (A) Mass spectrum of P2Y1R without ATP incubation
shows 100% binding to the drug, with no evidence for phosphorylation. (B) Mass
spectra recorded following addition of ATP at a 1:0.25 molar ratio of protein to
ADP show displacement of the drug by ATP. Stepwise increase of ATP to P2Y1R
from 1:0.5 and 1:2 molar ratios shows further displacement of the drug by ATP and
also evidence of a second putative binding site for ATP (bottom).3 of 6
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P2Y1R expression and purification
P2Y1R was overexpressed in insect cells, and the cell membranes
were enriched as described previously (18). To purify P2Y1R with-
out drug binding, the membranes were solubilized in 50 mM Hepes
(pH 7.5), 300 mM NaCl, 0.5% (w/v) DDM (Anatrace), and 0.1%
(w/v) cholesteryl hemisuccinate (CHS) (Sigma) for 3 hours at 4°C.
The debris was pelleted by centrifugation at 160,000g for 30 min,
and the supernatant was collected with supplement of imidazole
(pH 7.5) to a final concentration of 30 mM. After incubation of su-
pernatant with TALON immobilized metal affinity chromatography
resin (Clontech) overnight at 4°C, the resin was harvested and first
washed with 10 column volumes of 25 mM Hepes (pH 7.5), 300 mM
NaCl, 10% (v/v) glycerol, 40 mM imidazole, 0.05% (w/v) DDM, and
0.01% (w/v) CHS, followed by extensive washing with 10 column vol-
umes of 25 mM Hepes (pH 7.5), 300 mM NaCl, 10% (v/v) glycerol,
0.05% (w/v) DDM, 0.01% (w/v) CHS, 10 mMMgCl2, and 5 mM ATP
and 15 column volumes of 25 mM Hepes (pH 7.5), 300 mM NaCl,
10% (v/v) glycerol, 0.05% (w/v) DDM, and 0.01% (w/v) CHS. The
protein was eluted by 25 mM Hepes (pH 7.5), 300 mM NaCl, 10% (v/v)
glycerol, 300 mM imidazole, 0.05% (w/v) DDM, and 0.01% (w/v)Yen et al., Sci. Adv. 2017;3 : e1701016 16 June 2017CHS, followed by removing imidazole with PD MiniTrap G-25 col-
umn (GE Healthcare). The C-terminal His-tag and glycosylation of
receptor were further removed by treating PreScission protease (in-
house) and peptide N-glycosidase F (in-house) overnight. The pu-
rification of MRS2500-bound receptor followed the published
protocol (1).
Nondenatured MS for intact P2Y1R
Apo and drug-bound P2Y1R were buffer-exchanged into 200 mM
ammonium acetate containing DDM, foscholine, and CHS and im-
mediately introduced into a modified Q Exactive mass spectrometer
according to a previously reported method (20, 37). Briefly, a gentle
voltage gradient was applied (injection flatapole, inter-flatapole, bent
flatapole, and transfer multipole: 7.9, 6.94, 5.9, and 4 V, respectively) to
avoid the collisional activation of the ions before transferring into the
higher-energy collisional dissociation (HCD) cell. The optimized accel-
eration voltage (150 V) was then applied to the HCD cell to remove the
detergent micelle from the protein ions. Spectra were acquired with
10 microscans and averaged with a noise level parameter of 3. Backing
pressure wasmaintained at ~1.05 × 10−9 mbar to allow better transmis-
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Fig. 3. Comparison of mass spectra recorded for MRS2500 binding to phosphorylated and unmodified forms of P2Y1R. (A) Mass spectrum recorded following
addition of MRS2500 to P2Y1R assigned as follows: unmodified P2Y1R (blue background/square) with phosphorylation (green circle), endogenous ADP binding (red
circle), and MRS2500 binding to P2Y1R (orange background/hexagon). (i) Comparison of the peak heights of the 11+ charge state normalized to the phosphorylated
form of P2Y1R. (ii) Upon addition of MRS2500, the population of free P2Y1R is reduced relative to the phosphorylated form (−21 ± 4%) and (iii) concomitant binding to
the apo receptor is enhanced (17 ± 1.4%). (B) Schematic representation of ADP and drug binding to the phosphorylated receptor with phosphosites identified at the
C terminus [serine residues (green)]. ADP binding takes place with equal probability to phosphorylated and nonphosphorylated forms. By contrast, drug binding
occurs preferentially to the nonphosphorylated form.4 of 6
SC I ENCE ADVANCES | R E S EARCH ART I C L EProteomic analysis of P2Y1R
P2Y1R in protein purification buffer was digested with trypsin through
filter-aided samplepreparation (38,39). Proteinwas denatured in 100mM
ammonium bicarbonate buffer containing 8 M urea and 1% sodium
deoxycholate and transferred to Microcon YM-30 (Millipore) for fur-
ther reduction and alkylation by tris-(2-carboxyethyl)phosphine and
chloroacetamide. The tryptic peptides were harvested by centrifugation
after digestion. ForMS analysis, peptides were separated on anUltimate
3000 UHPLC system (Thermo Fisher Scientific) and electrosprayed di-
rectly into a Q Exactive mass spectrometer (Thermo Fisher Scientific)
through an EASY-Spray nanoelectrospray ion source (Thermo Fisher
Scientific). The peptides were trapped on a C18 PepMap100 precolumn
(300-mm inside diameter × 5 mm, 100 Å; Thermo Fisher Scientific)
using solvent A (0.1% formic acid in water) at a pressure of 500 bar.
The peptides were separated on a C18 PepMap RSLC Nano Easy col-
umn (2 mm, 100 Å; Thermo Fisher Scientific) using a linear gradient
[length, 30 min; 7 to 28% solvent B (0.1% formic acid in acetonitrile);
flow rate, 200 nl/min]. The raw data were acquired on the mass spec-
trometer in a data-dependent mode. Full-scan spectra were acquired in
theOrbitrap [scan range, 350 to 2000m/z; resolution, 70,000; automatic
gain control (AGC) target, 3 × 106; maximum injection time, 50 ms].
After the MS scans, the 20 most intense peaks were selected for HCD
fragmentation at 30%of normalized collision energy.HCDspectrawere
also acquired in the Orbitrap (resolution, 17,500; AGC target, 5 × 104;
maximum injection time, 120 ms), with first fixed mass at 180 m/z.
Phosphosite identification of P2Y1R
Raw MS data were processed by MaxQuant (version 1.5.0.35) for peak
detection and quantification. MS spectra were searched against the
UniProt Homo sapiens database (version 2013/04/03) as well as a list
of common contaminants using the Andromeda search engine (40, 41)
with the following search parameters: full tryptic or chymotryptic spec-
ificity, allowing two missed cleavage sites; fixed modification was set to
carbamidomethyl (C); and the variable modification was set to acetyla-
tion (protein N terminus) and oxidation (M). Mass spectra were recali-
bratedwithinMaxQuantwith a precursor error tolerance of 20 parts per
million (ppm) and then re-searched with amass tolerance of 5 ppm. The
search results were filtered with a false discovery rate of 0.01 for proteins,
peptides, and peptide spectra matches.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/6/e1701016/DC1
fig. S1. Dissociation of the P2Y1R-MRS2500 complex in the gas phase.
fig. S2. Mass spectrum of wild-type P2Y1R incubated with different molar ratios of ATP.
table S1. Measured and calculated mass differences of P2Y1R in apo and ligand-bound forms.
table S2. P2Y1R phosphopeptides identified by liquid chromatography–MS/MS analysis.REFERENCES AND NOTES
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